We are live on
!
Find out more
NFC
Northeast Financial Consultants Portfolio holdings
AUM
$2.45B
1-Year Est. Return
15.14%
This Fund
S&P 500
This Quarter
Est. Return
+3.44%
1 Year Est. Return
+15.14%
3 Year Est. Return
+63.77%
5 Year Est. Return
+108.46%
10 Year Est. Return
+198.58%
AUM
$170M
AUM Growth
+$20.4M
(+14%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
6.9%
Top 10 Holdings %
Top 10 Hldgs %
51.44%
Holding
128
New
29
Increased
22
Reduced
25
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco S&P Spin-Off ETF
CSD
|
+$1.92M |
| 2 |
Invesco Pharmaceuticals ETF
PJP
|
+$1.32M |
| 3 |
Biogen
BIIB
|
+$1.23M |
| 4 |
WisdomTree US MidCap Fund
EZM
|
+$1.04M |
| 5 |
Invesco BuyBack Achievers ETF
PKW
|
+$1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RDS.B
Royal Dutch Shell PLC ADS Class B
RDS.B
|
+$2.42M |
| 2 |
HMA
HEALTH MGMT ASSOC INC CL-A
HMA
|
+$1.29M |
| 3 |
Reinsurance Group of America
RGA
|
+$515K |
| 4 |
The Mosaic Company
MOS
|
+$399K |
| 5 |
Suburban Propane Partners
SPH
|
+$347K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.03% |
| 2 | Energy | 28.07% |
| 3 | Financials | 6.36% |
| 4 | Technology | 4.61% |
| 5 | Materials | 4.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$144B
| $38.6M | 22.71% |
1,266,044
+6,847
| +0.5% | +$204K |
|
2
Plains All American Pipeline
PAA
$17.2B
| $8.26M | 4.86% |
149,819
-2,547
| -2% | -$134K |
|
3
Enterprise Products Partners
EPD
$83.6B
| $6.31M | 3.71% |
181,966
+7,244
| +4% | +$240K |
|
|
CYHHZ
4
DELISTED
Community Health Systems, Inc. Series A Contingent Value Rights
CYHHZ
| $5.92M | 3.49% |
+98,732
| New | +$5.48K |
|
5
Chevron
CVX
$374B
| $5.54M | 3.26% |
46,600
-840
| -2% | -$97.7K |
|
|
MMP
6
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $5.52M | 3.25% |
79,211
+4,017
| +5% | +$267K |
|
7
International Flavors & Fragrances
IFF
$20.2B
| $5.4M | 3.18% |
56,474
| – | – |
|
8
MetLife
MET
$62.7B
| $4.22M | 2.48% |
89,666
+9,729
| +12% | +$447K |
|
9
ExxonMobil
XOM
$634B
| $3.93M | 2.32% |
40,277
-600
| -1% | -$57.2K |
|
|
KMP
10
DELISTED
KINDER MORGAN ENER PNTRS L.P.
KMP
| $3.7M | 2.18% |
50,001
+2,726
| +6% | +$212K |
|
|
ETP
11
DELISTED
Energy Transfer Partners L.p.
ETP
| $3.64M | 2.14% |
67,600
-1,500
| -2% | -$81.4K |
|
12
Alphabet (Google) Class C
GOOG
$4.07T
| $3.29M | 1.94% |
118,482
+762
| +0.6% | +$22.2K |
|
|
EEP
13
DELISTED
Enbridge Energy Partners
EEP
| $2.75M | 1.62% |
100,403
-5,862
| -6% | -$164K |
|
|
KMR
14
DELISTED
KINDER MORGAN MANAGEMENT LLC
KMR
| $2.3M | 1.36% |
33,775
-919
| -3% | -$63.8K |
|
15
Johnson & Johnson
JNJ
$643B
| $2.18M | 1.28% |
22,159
-500
| -2% | -$46.4K |
|
|
16
Invesco S&P Spin-Off ETF
CSD
$223M
| $2.17M | 1.27% |
47,755
+42,850
| +874% | +$1.92M |
|
|
17
Invesco Pharmaceuticals ETF
PJP
$447M
| $2.12M | 1.25% |
37,487
+23,285
| +164% | +$1.32M |
|
|
WPZ
18
DELISTED
WILLIAMS PARTNERS L.P. COM UTS REPTG L.P. INT
WPZ
| $2.12M | 1.25% |
44,159
-6,847
| -13% | -$322K |
|
19
GE Aerospace
GE
$377B
| $1.89M | 1.11% |
15,208
-2,295
| -13% | -$284K |
|
20
KKR & Co
KKR
$92.2B
| $1.89M | 1.11% |
82,575
-2,000
| -2% | -$48.4K |
|
|
HDV
21
iShares Core High Dividend ETF
HDV
$14.7B
| $1.88M | 1.1% |
131,285
+12,605
| +11% | +$175K |
|
22
Vertex Pharmaceuticals
VRTX
$124B
| $1.65M | 0.97% |
23,385
+3,385
| +17% | +$268K |
|
23
Blackstone
BX
$107B
| $1.53M | 0.9% |
47,001
-2,038
| -4% | -$65K |
|
24
L3Harris
LHX
$56.9B
| $1.35M | 0.79% |
18,456
| – | – |
|
|
AMJ
25
DELISTED
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
| $1.35M | 0.79% |
29,000
-1,250
| -4% | -$57.7K |
|
Similar funds
MC
WBA
MD
GL
SVCF
GLA
HIP
MME
Northeast Financial Consultants's Q1 2014 Portfolio in Review
As of Q1 2014, Northeast Financial Consultants held 128 positions worth $170M, up 14% from $149M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Northeast Financial Consultants deployed $11.7M of net new capital in Q1 2014, opening 29 new positions and adding to 22 existing holdings. Its largest new stake was Biogen: 3,861 shares worth $1.18M.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 30% a quarter earlier, followed by Energy and Financials.
On the sell side, the largest reduction was Royal Dutch Shell PLC ADS Class B, an estimated $2.42M trimmed.
- Northeast Financial Consultants's largest Q1 2014 buy was Biogen: 3,861 shares worth $1.18M.
- Northeast Financial Consultants added most to Invesco S&P Spin-Off ETF in Q1 2014, an estimated $1.92M increase.
- Northeast Financial Consultants's biggest Q1 2014 reduction was Royal Dutch Shell PLC ADS Class B, cutting an estimated $2.42M.
- Northeast Financial Consultants fully exited HEALTH MGMT ASSOC INC CL-A in Q1 2014, selling an estimated $1.29M.
- Northeast Financial Consultants's ten largest holdings make up 51% of its $170M portfolio in Q1 2014.
- Northeast Financial Consultants opened 29 new positions and closed 12 in Q1 2014.
- Northeast Financial Consultants's portfolio value rose 14% quarter-over-quarter to $170M.
Based on Northeast Financial Consultants's 13F filing for Q1 2014, filed 1 May 2014.